{
  "id": "56c1f003ef6e394741000039",
  "type": "factoid",
  "question": "What molecule is targeted by suvorexant?",
  "ideal_answer": "Suvorexant is a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/22920041",
    "http://www.ncbi.nlm.nih.gov/pubmed/25489915",
    "http://www.ncbi.nlm.nih.gov/pubmed/25406050",
    "http://www.ncbi.nlm.nih.gov/pubmed/25533960",
    "http://www.ncbi.nlm.nih.gov/pubmed/25667197",
    "http://www.ncbi.nlm.nih.gov/pubmed/23197752",
    "http://www.ncbi.nlm.nih.gov/pubmed/24757363",
    "http://www.ncbi.nlm.nih.gov/pubmed/25397996",
    "http://www.ncbi.nlm.nih.gov/pubmed/21473737",
    "http://www.ncbi.nlm.nih.gov/pubmed/26478806"
  ],
  "snippets": [
    {
      "text": "Suvorexant is the first DORA to be approved and has demonstrated efficacy at decreasing both time to sleep onset and increasing total sleep time compared with placebo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26478806",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25667197",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSION: Suvorexant is the first dual orexin receptor antagonist approved for the treatment of insomnia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25667197",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25533960",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " The human OX2 receptor (OX2R) belongs to the \u03b2 branch of the rhodopsin family of GPCRs, and can bind to diverse compounds including the native agonist peptides orexin-A and orexin-B and the potent therapeutic inhibitor suvorexant. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25533960",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23197752",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21473737",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The neurotransmitter systems on which the development of these agents were based included serotonin for ondansetron and lorcaserin, dopamine for varenicline, substance P (or neurokinin) for aprepitant, melatonin for ramelteon, and orexin for suvorexant. The indications were chemotherapy-induced nausea and vomiting for ondansetron and aprepitant, smoking cessation for varenicline, weight loss for lorcaserin, and insomnia for suvorexant and ramelteon.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25406050",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Suvorexant, a dual orexin receptor antagonist for the management of insomnia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24757363",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Suvorexant, a dual orexin receptor antagonist for the management of insomnia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24757363",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The orexin-1 and orexin-2 receptors are two G protein-coupled receptors that bind the neuropeptides orexin-A and orexin-B. Dual antagonism of the receptors by small molecules is clinically efficacious in the treatment of insomnia, where the most advanced molecule suvorexant has recently been approved.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25489915",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Suvorexant helps in decreasing wakefulness by counteracting orexin activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25397996",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The orexin-1 and orexin-2 receptors are two G protein-coupled receptors that bind the neuropeptides orexin-A and orexin-B. Dual antagonism of the receptors by small molecules is clinically efficacious in the treatment of insomnia, where the most advanced molecule suvorexant has recently been approved.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25489915",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Hypnotic drug development has arguably become more focused in recent years, particularly upon the highly anticipated novel target, the orexin (hypocretin) system. Merck&apos;s suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor antagonist (DORA) class expected to be submitted for FDA approval, with a new drug application anticipated in 2012.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22920041",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "orexin"
}